Michael Frederick Press, MD, PhD

Professor of Pathology

Harold E. Lee Chair in Breast Cancer Research

Director of Breast Cancer Analysis Lab

Image of Michael Frederick Press, MD, PhD
Is this your profile? Click to edit

Overview

Michael F. Press, M.D., Ph.D. is a professor in the Department of Pathology and co-leader of the Women’s Cancers Program. He received his M.D., Ph.D. and residency training at the University of Chicago. He was a member of the University of Chicago faculty for seven years before joining the faculty of the University of Southern California in 1988. Dr. Press is currently the director for the Breast Cancer International Research Group Central Laboratory, the coordinator of the Breast Cancer Program at USC Norris Cancer Center and holds the Harold E. Lee Chair in Cancer Research in the USC Norris Cancer Center. His research interests are molecular genetic alterations in breast and gynecologic cancers.

Research Funding

  • HER-2 NEU PROTO-ONCOGENE IN OVARIAN &ENDOMETRIAL CANCER
    NIH · R01CA050589 · Feb 1, 1991 – Jan 31, 1995 · Role: Principal Investigator
  • PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    NIH · R01CA048780 · Apr 1, 1988 – Jan 31, 2006 · Role: Principal Investigator

Publications

  • Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun. 2020 11 17; 11(1):5824.. View in PubMed
  • Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stains. Nat Commun. 2020 11 16; 11(1):5727.. View in PubMed
  • Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. Breast Cancer Res Treat. 2020 Nov; 184(2):311-324.. View in PubMed
  • Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE. J Clin Oncol. 2021 01 01; 39(1):79-89.. View in PubMed
  • Testing considerations for phosphatidylinositol-3-kinase catalytic subunit alpha as an emerging biomarker in advanced breast cancer. Cancer Med. 2020 09; 9(18):6463-6472.. View in PubMed
  • A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190.. View in PubMed
  • Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). Clin Breast Cancer. 2020 06; 20(3):183-193.. View in PubMed
  • Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2- Breast Cancer. Clin Cancer Res. 2020 02 01; 26(3):566-580.. View in PubMed
  • Circulating Tumor Cells Exhibit Metastatic Tropism and Reveal Brain Metastasis Drivers. Cancer Discov. 2020 01; 10(1):86-103.. View in PubMed
  • A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer. Clin Breast Cancer. 2020 06; 20(3):e251-e260.. View in PubMed